ReviewAutoimmune diseases2013
Genetics of psoriasis and pharmacogenetics of biological drugs.
Review in Autoimmune diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis.The Cochrane database of systematic reviews · 2020Pooled it
- Meta-analysis of the TNFAIP3 region in psoriasis reveals a risk haplotype that is distinct from other autoimmune diseases.Genes and immunity · 2015Pooled it
- Paired longitudinal tear proteomics reveals persistent ocular surface dysregulation after teprotumumab therapy in thyroid eye disease.Communications medicine · 2026Article
- Psoriasis and Seborrheic Keratoses: Insights from Biologic Therapy and Skin Imaging.Life (Basel, Switzerland) · 2025Article
- Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers.Biomedicines · 2024Article
- The Genetic Susceptibility to Psoriasis and the Relationship of Linked Genes to Our Treatment Options.International journal of molecular sciences · 2023Review
- Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine.International journal of molecular sciences · 2023Review
- Towards Personalized Medicine in Psoriasis: Current Progress.Psoriasis (Auckland, N.Z.) · 2022Review
- Article
- Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis.Journal of personalized medicine · 2020Article
- Pharmacogenetics Update on Biologic Therapy in Psoriasis.Medicina (Kaunas, Lithuania) · 2020Review
- Pathological role of excessive DNA as a trigger of keratinocyte proliferation in psoriasis.Clinical and experimental immunology · 2020Article
- The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Review
- Diagnosis, Screening and Treatment of Patients with Palmoplantar Pustulosis (PPP): A Review of Current Practices and Recommendations.Clinical, cosmetic and investigational dermatology · 2020Review
- Long-range PCR libraries and next-generation sequencing for pharmacogenetic studies of patients treated with anti-TNF drugs.The pharmacogenomics journal · 2019Article
- Psoriasis: Association of interleukin-17 gene polymorphisms with severity and response to treatment.Experimental and therapeutic medicine · 2019Review
- Quo vadis, biological treatment for psoriasis and psoriatic arthritis?Postepy dermatologii i alergologii · 2018Review
- Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis.The pharmacogenomics journal · 2018Article
- New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis.The pharmacogenomics journal · 2018Article
- The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.Dermatology and therapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic inflammatory disease of the skin. The causes of psoriasis are unknown, although family and twin studies have shown genetic factors to play a key role in its development. The many genes associated with psoriasis and the immune response include TNF α , IL23, and IL12. Advances in knowledge of the pathogenesis of psoriasis have enabled the development of new drugs that target cytokines (e.g., etanercept, adalimumab, and infliximab, which target TNF α , and ustekinumab, which targets the p40 subunit of IL23 and IL12). These drugs have improved the safety and efficacy of treatment in comparison with previous therapies. However, not all patients respond equally to treatment, possibly owing to interindividual genetic variability. In this review, we describe the genes associated with psoriasis and the immune response, the biological drugs used to treat chronic severe plaque psoriasis, new drugs in phase II and III trials, and current knowledge on the implications of pharmacogenomics in predicting response to these treatments.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.